TAM receptors (Tyro3
, Axl, MerTK) are receptor tyrosine kinases (RTKs) expressed in innate immune cells.
The technology blocks ligand (Gas6) binding, thereby inhibiting TAM (Tyro3
, Axl, and Mertk)-mediated activation of cellular processes that may lead to aggressive growth and spread of tumours.
This family of cell surface transmembrane receptors has three members: TYRO3
, AXL, and MERTK.
These receptors include scavenger receptors (e.g., CD36, SR1, and macrophage receptor with collagenous structure (MARCO)), low-density lipoprotein (LDL) receptor family members (e.g., LDLR, ApoER2, and VLDL), and three receptor tyrosine kinases (Tyro3
, Axl, and Mertk) [5, 26].
(72) Additional receptors reported for ZIKV include T-cell immunoglobulin and mucin domain (TIM1) TYRO3
, and AXL.
The DNA breakage surveillance protein Chk1 and the TYRO3
which was required for G1/S transition in breast cancer cell decreased as well.
Another molecule identified as an entry factor for DENV is AXL  which belongs to the TYRO3
AXL MER (TAM) family, a group of tyrosine kinase receptors involved in the clearance of apoptotic cells and regulation of innate immunity [15,16].
Soon after it was recognized as a growth factor-like molecule, as it interacted with receptor tyrosine kinases (RTKs) of the TAM family; Tyro3
, Axl, and MerTK.
Sitravatinib is an investigational spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3
, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
The technology blocks ligand binding, thereby inhibiting TAM (Tyro3
, Axl, and Mertk)-mediated activation of cellular processes that may lead to aggressive growth and spread of tumors.